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The WHIM syndrome, which features high suscepti-
bility to human papillomavirus (HPV) infection, is
a rare immunodeficiency associated with autosomal
dominant heterozygousmutationsof theCXCR4che-
mokine receptor. CXCL12 and its receptors, CXCR4
and CXCR7, are linked to tumorigenesis, and we
reported that abnormal expression of CXCL12 in
epidermal keratinocytes correlates with HPV infec-
tion.However, theHPV-relatedpathologiesobserved
in WHIM patients remain mechanistically unex-
plained. We show that keratinocytes immortalized
by oncogenic HPV16 or HPV18 upregulate CXCL12
and its receptors in a manner dependent upon
expression of the viral proteins E6 and E7. Autocrine
signaling activated by CXCL12-engagement of its
receptors controls motility and survival of the
infected cells. Strikingly, expression of a WHIM
syndrome-related gain-of-function CXCR4 mutant
confers transforming capacity to HPV18-immortal-
ized keratinocytes. These results establish a pivotal
role for CXCL12 signaling in HPV-mediated transfor-
mation and provide a mechanistic basis for under-
standing HPV pathogenesis in WHIM syndrome.
INTRODUCTION
The WHIM syndrome, which features human papillomavirus
(HPV)-induced warts, hypogammaglobulinemia, infections, and
myelokathexis (i.e., abnormal retention of senescent neutrophils
in the bone marrow associated with peripheral neutropenia), is
a rare combined immunodeficiency mediated through dysfunc-
tion of CXCR4 (Hernandez et al., 2003). CXCR4 is a G protein-
coupled receptor (GPCR) with a unique natural ligand, theCell Host &chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12
(Bleul et al., 1996; Oberlin et al., 1996). Binding of CXCL12 to
CXCR4 triggers typical activation of Gai protein-dependent
pathways of a chemokine receptor that are regulated in a timely
manner by the recruitment of b-arrestins to the receptor, which
precludes further G protein activation (i.e., desensitization).
More recently, b-arrestins were found to link most activated
GPCRs, including CXCR4, to additional signaling pathways
involved in cytoskeleton reorganization and antiapoptotic
signaling, such as the mitogen-activated protein kinase family
(Busillo and Benovic, 2007). In WHIM, dysfunction of CXCR4 is
linked to inherited heterozygous autosomal dominant gain-of-
function mutations in the receptor gene, leading to increased
and prolonged G protein- and b-arrestin-dependent responses
associated with an impaired desensitization (Balabanian et al.,
2005b; Hernandez et al., 2003; Kawai et al., 2005; Lagane
et al., 2008). Although the CXCR4-CXCL12 axis controls leuko-
cyte trafficking and homing, thus providing a plausible mecha-
nism accounting for the hematological defects in WHIM patients
and, notably, the myelokathexis (Kawai et al., 2007), how these
patients display a selective susceptibility to HPV infection is still
unknown.
HPVs are double-stranded DNA viruses with a tropism for
epithelial keratinocytes, causing chronic skin and mucosal
lesions that can progress to cancer according to virus types
(Mu¨nger and Howley, 2002). HPV pathogenesis in patients
suffering from WHIM manifests as profuse and persistent
cutaneous warts and, in some adults, as intractable genital
condyloma acuminata that often develop as severe dysplasia
and carcinoma (Balabanian et al., 2005b; Diaz and Gulino,
2005; Gorlin et al., 2000; Tarzi et al., 2005; Wetzler et al.,
1992). Although they have not been extensively characterized,
these mucosal lesions are presumably associated with low-risk
HPVs (such as HPV6 or HPV11, data not shown) that, in contrast
to high-risk oncogenic types (such as HPV16 and HPV18), do not
generally cause cancer. WHIM patients do not suffer from other
viral infections, suggesting that the selective susceptibility to
HPV is related to their genetic disorder. A specific failure ofMicrobe 8, 523–533, December 16, 2010 ª2010 Elsevier Inc. 523
Figure 1. Human Keratinocytes Immortal-
ized In Vitro by High-Risk HPVs Express
CXCL12
(A) Intracellular detection of CXCL12 by immuno-
fluorescence. Control stainings were HaCaT cells
transfected with a vector encoding CXCL12
(+ CXCL12 cDNA) or an empty vector (‘‘vector’’)
and HK-HPV18 cells stained in presence of
CXCL12 (+ 10 mM CXCL12). Lower: ‘‘Control’’
corresponds to cells stained with the IgG2a iso-
type control. Blue indicates nuclei counter-
stained with Hoechst 33342. The scale bar
represents 10 mm. The original magnification
was 633.
(B) Left: Representative histograms of intracel-
lular CXCL12 detection (open histograms) by
flow cytometry as compared to isotype control
mAb (gray histograms). Right: CXCL12 expres-
sion is presented as mean fluorescence intensity
(MFI) ± standard error of the mean (SEM)
(n = 3–6). *p < 0.05 and **p < 0.005 compared
with HK-Normal cells. See also Figure S1.
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CXCL12/HPV-Interplay and Tumorigenesisanti-HPV immune responses is unlikely, especially in light of
recent findings demonstrating the generation of protective
immunity in a WHIM patient after administration of a tetravalent
HPV vaccine (Handisurya et al., 2010). Recently, we discovered
that CXCL12, which is detected neither in keratinocytes of nor-
mal epidermis nor in various local and systemic-associated skin
pathologies, is expressed in low-grade HPV-induced lesions,
whether they originate from WHIM patients or not (Balabanian
et al., 2005b; Pablos et al., 1999). We thus hypothesized that
the CXCL12-CXCR4 axis represents a host susceptibility factor
for HPV-associated carcinogenic progression, as exemplified
in an acute manner in the context of the CXCR4 dysfunctions
associated with WHIM.
CXCL12wasoriginally isolated frombonemarrowstromal cells
(Nagasawa et al., 1994) and is now known to be expressed by
both hematopoietic and nonhematopoietic cells in various
tissues and to control, beside the chemotaxis of leukocytes,
numerous physiological and pathological processes. For
instance,CXCL12expression,which is constitutive in fibroblasts,
dendritic cells, and endothelial cells of human skin (Pablos et al.,
1999), is markedly increased at the site of skin injury (Avniel et al.,
2006; Grunewald et al., 2006; Toksoy et al., 2007) where it partic-
ipates in thewound healing process (Florin et al., 2005; Gallagher
et al., 2007; Grunewald et al., 2006). Since evidence in the early
2000s that CXCL12 is involved in the development of breast
and prostate cancers (Mu¨ller et al., 2001; Taichman et al.,
2002), expression of this chemokine has been documented in
various types of tumors (Kryczek et al., 2007). The expression
levels of CXCR4 have prognostic significance in different kinds
of humancancers (Rubin, 2009), and thoseofCXCR7, the second
CXCL12 receptor identified in 2005 (Balabanian et al., 2005a;
Burns et al., 2006), are also high in cancer cells (Maksym et al.,
2009). Nevertheless, the events that control the expression and524 Cell Host & Microbe 8, 523–533, December 16, 2010 ª2010 Elseaction of both CXCR4 and CXCR7 in tumor microenvironment
are mostly unknown.
Here, we examined the functional interplay between the
CXCL12-signaling axis and high-risk HPV16 and HPV18 gene
expression. Our results identified an autocrine CXCL12-
CXCR4/CXCR7-dependent signaling activated by the viral onco-
genes E6 and E7 as a mechanism essential for HPV-mediated
cell transformation.
RESULTS
HumanKeratinocytes Immortalized In Vitro by High-Risk
HPVs Express CXCL12
To investigate the role of CXCL12 and its interplay with HPV, we
set up in vitro models by taking advantage of the immortalization
of primary human keratinocytes promoted by HPV16 and 18. We
examined expression of CXCL12 in four cell lines, a spontane-
ously immortalized human keratinocyte cell line (HaCaT), primary
human keratinocytes (HK-Normal), and two keratinocyte cell
lines immortalized by HPV16 and HPV18 (HK-HPV16 and 18).
Expression of CXCL12 was low in both HaCaT and HK-Normal
cells, whereas it was high in both HK-HPV16 and HK-HPV18
cells (Figure 1A). The specificity of CXCL12 staining was
confirmed by its detection in HaCaT cells upon ectopic expres-
sion of the chemokine and by the absence of labeling with the
matched isotype control (Figure 1A). Furthermore, CXCL12
staining disappeared in HK-HPV18 cells in the presence of
excess CXCL12 (Figure 1A). Quantitative analyses by flow
cytometry revealed that CXCL12 levels in HK-HPV16 (mean
fluorescence intensity [MFI], 28.4 ± 4.4) and HK-HPV18
(MFI, 35.2 ± 5.9) cells are almost 3-fold higher than those found
in HK-Normal cells (MFI, 13.4 ± 3.6) (Figure 1B). This result thus
confirmed our previous in vivo observations that CXCL12 isvier Inc.
Figure 2. CXCL12 Is Immobilized at the Surface of
HK-HPV18 Cells
(A) Upper: Dot-plot showing cell surface levels of CXCL12
(lower right quadrants) in HK-HPV18 cells treated or not
with heparitinase I. Lower: staining with isotype control
mAb. Histograms represent the percentage of CXCL12-
positive cells (% ± SEM; n = 2 experiments performed in
duplicates) as compared to nontreated cells (set at
100%). ***p < 0.0005.
(B) Cell surface HS expression with the anti-HSmAb (open
histograms). Filled histograms indicate staining with IgM
isotype control. Numbers in the top right corner of
histograms represent HS expression (MFI ± SEM; n = 2
experiments performed in duplicates).
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CXCL12/HPV-Interplay and Tumorigenesisabnormally expressed in epithelial keratinocytes of lesions
induced by HPV (Balabanian et al., 2005b).
CXCL12 Is Immobilized at the Surface
of HK-HPV18 Cells
Although HPV-immortalized keratinocytes displayed significant
increase in intracellular CXCL12 levels, we failed to detect
secretion of the chemokine in the cell culture mediumwith ELISA
and functional assays (see also Figure S1, available online). We
thus looked for membrane-tethered CXCL12 because most
chemokines, including CXCL12, can be immobilized at the cell
surface through their binding to glycosaminoglycans of the
proteoglycan family such as heparan sulfate (HS) (Amara et al.,
1999; Handel et al., 2005). CXCL12 was revealed at the cell
surface by using the K15C mAb (Figure 2A, left). This mAb
recognizes the N-terminal domain of CXCL12 that is required
for the binding to CXCR4 and its activation and that remains
exposed upon interaction between the chemokine and HS
(Amara et al., 1999). Treatment with heparitinase I, which specif-
ically degrades HS (Figure 2B), significantly decreased CXCL12
staining (Figure 2A). This indicates that HS participates to the
immobilization of CXCL12 at the surface of HPV-immortalized
keratinocytes.Cell Host & Microbe 8, 523–Neutralization of the CXCL12-CXCR4-
Signaling Axis Impairs Migration
of HPV-Immortalized Keratinocytes
Binding of CXCL12 to HS could enhance the
capacity of the chemokine to interact with
CXCR4 (Handel et al., 2005), and interaction
between CXCL12 and CXCR4 is known to
hinder the binding of the anti-CXCR4 12G5
mAb to the receptor (Hesselgesser et al.,
1998; Heveker et al., 1998). We therefore antic-
ipated that the membrane-bound CXCL12,
once engaged to its receptor, would hinder
detection of CXCR4 by the 12G5 mAb in
HK-HPV cells. Surprisingly, levels of CXCR4
detected at the surface of HK-HPV cells by
the 12G5 mAb were not diminished when
compared to normal keratinocytes (Figure 3A).
This apparent paradox could be explained by
the concomitant increase of CXCR4 and
CXCL12 at the surface of HK-HPV cells.
Indeed, after a brief ice-cold acidic glycinewash, which removes surface-bound chemokines (Amara
et al., 1997; Bowen-Pope and Ross, 1985), we observed a 6-
to 10-fold increase in the levels of CXCR4 detected at the
surface of HK-HPV cells, whereas no significant change was
observed in normal primary keratinocytes (Figure 3A). Acid
wash increased the MFI of CXCR4 staining from 7.2 ± 2.1 to
71.0 ± 5.5 in HK-HPV16 cells, from 12.6 ± 4.4 to 80.2 ± 17.0
in HK-HPV18 cells, and from 7.8 ± 1.1 to 17.7 ± 6.6 in primary
keratinocytes. These results indicated that the levels of
CXCR4 are increased at the membrane of HK-HPV cells and
that a large fraction of the receptor is engaged with CXCL12.
To examine the functionality of this CXCL12-CXCR4 interaction,
we analyzed the consequence of its blockade on the migration
of HPV-immortalized keratinocytes in a wound healing model.
Wounding of the HK-HPV cell monolayer initiated a synchronous
migration of the cells at the edge, which filled the gap in 8 to
12 hr (Figure 3B, nontreated, t = 0 hr versus t = 8 hr), a time
lapse shorter than cell division. Staining of polymeric F-actin
by TRIC-conjugated phalloidin indicated that the cells at the
leading edge display protrusion of actin-rich structures (lamelli-
podial and filopodial extensions) that are generally associated
with cell motility (see also Figure S2A). We then compared the
extent of wound closure upon interference of CXCL12-CXCR4533, December 16, 2010 ª2010 Elsevier Inc. 525
Figure 3. Neutralization of the CXCL12-
CXCR4-Signaling Axis Impairs Migration of
HPV-Immortalized Keratinocytes
(A) Comparison of CXCR4 expression at the
surface of HK-Normal cells (HK-N) and HK-HPV16
or -HPV18 cells (HK-16 and HK-18, respectively)
with the anti-CXCR4 12G5 (open histograms)
and the IgG2a isotype control mAbs (gray histo-
grams). Cells were treated with an acidic buffer
(acid wash) or left untreated (no treatment). Data
are MFI ± SEM (n = 3–6). **p < 0.005 and
***p < 0.0005 compared with HK-N cells.
(B) Confluent cell monolayers were left untreated
or were incubated overnight with chalcone 4 or
AMD3100 at the indicated concentrations before
wounding. Cells were fixed immediately (t = 0 hr)
or 8 hr after wounding (t = 8 hr) and were visualized
with TRITC-tagged phalloidin (red staining) and
Hoechst 33342 (blue) (n = 2–3 experiments per-
formed in duplicates). Values represent area of
the wound in mm2 ± SEM. *p < 0.05, **p < 0.005,
and ***p < 0.0005 compared with nontreated cells
at t = 8 hr. The scale bar represents 50 mm. The
original magnification was 253. See also Figure S2
and Movie S1.
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CXCL12/HPV-Interplay and Tumorigenesisinteraction by AMD3100, an antagonist of CXCR4 (De Clercq,
2003), or chalcone 4, a neutraligand that binds directly to the
chemokine (Hachet-Haas et al., 2008). Treatment with either
drug significantly inhibited wound closure, although the inhibi-
tion was stronger with chalcone 4 (Figure 3B). Time-lapse
microscopy indicated that the wounds in cells treated with chal-
cone 4 did not close up within 24 hr after scratching (see also
Figure S2B and Movie S1), suggesting that CXCL12 neutraliza-
tion impaired migration of HK-HPV cells. Moreover, wounds in
primary HK-Normal cells’ monolayer did not close up within
14 hr (see Figure S2C) in accordance with the low levels of
CXCL12 detected in those cells (Figure 1). Overall, these results
revealed a concomitant increase in CXCR4 and CXCL12 levels
in HK-HPV cells leading to functional CXCL12-CXCR4 interac-
tions that control cell migration.Both CXCR4 and CXCR7 Are Expressed at the Surface
of HK-HPV Cells
Whereas AMD3100 is a selective and competitive CXCR4
antagonist (Burns et al., 2006; Kalatskaya et al., 2009), chal-
cone 4 inhibits the binding of CXCL12 to both CXCR4 and
CXCR7 (Hachet-Haas et al., 2008). Using biotinylated-526 Cell Host & Microbe 8, 523–533, December 16, 2010 ª2010 Elsevier Inc.CXCL12 (CXCL12-biot) as a tracer, we
observed that binding of CXCL12-biot
to HK-HPV cells was reduced (90%)
by addition of untagged CXCL12 or chal-
cone 4 (Figure 4A). AMD3100 also dis-
placed the tracer but only partially, sug-
gesting that HK-HPV cells also express
CXCR7 at their surface. We found that
the CXCL11 chemokine, which also
interacts with CXCR7 (Burns et al.,
2006), displaces only partially thebinding of CXCL12-biot (Figure 4B), thus demonstrating that
CXCL12 indeed binds to both CXCR7 and CXCR4. Flow cytom-
etry analyses with the neutralizing anti-CXCR7 9C4 mAb
detected comparable levels of this receptor at the surface of
control and HK-HPV cells (Figure 4C). As for CXCR4, a stronger
staining was obtained upon acidic washing, thus demonstrating
that expression of both CXCR4 and CXCR7 are enhanced in
HK-HPV cells and that a large fraction of both receptors is
occupied by CXCL12 (Figure 4C). Together with the fact that
chalcone 4 strongly prevented wound healing (Figure 3B), these
results show that both CXCR4 and CXCR7 are functional in
HK-HPV cells.CXCL12-Mediated Cell Proliferation and Survival
Involve Interaction with Both CXCR4 and CXCR7
Although CXCR7 fails to induce typical G protein-dependent
responses (Thelen and Thelen, 2008), evidence indicates that
CXCR7 can signal and regulate cell proliferation, adhesion, and
chemotaxis (Maksym et al., 2009). We therefore measured the
role of CXCR7 in the proliferative functions of CXCL12. We found
that mAb-mediated blockade of the CXCR7 significantly
inhibited cell proliferation, as measured with BrdU incorporation
Figure 4. Both CXCR4 and CXCR7 Are Ex-
pressed at the Surface of HK-HPV Cells
(A and B) Binding of biotinylated-CXCL12
(CXCL12-biot) to HK-HPV18 cells was detected
after addition of streptavidin-PE conjugate. Data
represent MFIs of streptavidin-PE bound to biot-
CXCL12 (n = 2 experiments performed in tripli-
cates). Concentration-dependent inhibition of
CXCL12-biot binding by AMD3100 (A) and
CXCL11 (B) is shown. Values were normalized
for total binding (set at 100%) and are expressed
as mean ± SEM. **p < 0.005 and ***p < 0.0005
compared with total binding.
(C) Cell surface expression of CXCR7 in HK-N,
HK-16, and HK-18 with the anti-CXCR7 9C4
mAb in cells treated or not with an acidic buffer.
Results are expressed as MFI ± SEM (n = 2–6).
*p < 0.05 compared with nontreated cells.
**p < 0.005 and ***p < 0.0005 compared with
HK-N cells.
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in the presence of chalcone 4 (Figure 5A, left) or anti-CXCL12
antibody (see also Figure S3A). Silencing of CXCR7 by short
hairpin RNAs (shRNA) that specifically reduced CXCR7 but not
CXCR4 at the cell surface (Figure 5B) also reduced proliferation
(Figure 5A, right). In addition, HK-HPV cells treated with an
anti-CXCR4neutralizing antibodyorAMD3100exhibited a similar
reduction in proliferation to those treated with the anti-CXCR7
antibody alone (see also Figure S3B), therefore demonstrating
the contribution of both receptors. Annexin-V staining indicated
that 90% of the cells undergo apoptosis upon CXCL12 neutrali-
zation with chalcone 4 (Figure 5C). This result suggests that the
regulation of cell proliferation by the CXCL12-CXCR4/CXCR7
axis is due, at least in part, to an enhanced cell survival.
To gain further insight into the functional response elicited
by the CXCL12-signaling axis, we investigated the activation
of the protein kinase B/Akt, which plays a role in the stability
of CXCR4 (Li et al., 2004; Slagsvold et al., 2006) as well as in
cell proliferation, survival, and migration (Cantley, 2002; Liu
et al., 2009; Manning and Cantley, 2007). We observed a high-
constitutive PI3K-dependent phosphorylation of Akt in
HK-HPV18 cells (Figure 5D and see also Figure S3C). This
constitutive activation was reduced up to 70% upon addition
of chalcone 4 (Figure 5E) and was significantly decreased by
the neutralizing anti-CXCR7 mAb 9C4 and by silencing of
CXCR7 with a shRNA approach (Figure 5F). Our results thus
revealed the essential role of CXCL12-CXCR7 interactions in
HK-HPV cell proliferation and survival.Cell Host & Microbe 8, 523–533, DHPV-E6/E7 Expression Is
Responsible for the Increased
Levels ofCXCL12 and Its Receptors
We then investigated whether the two
viral oncogenes, E6 and E7, are involved
in the upregulation of CXCL12 and its
receptors in HPV-immortalized cells. We
expressed the HPV18-E2 protein in
HK-HPV cells using a lentiviral transduc-
tion approach. The E2 protein is a tran-scriptional repressor of the E6/E7 genes that are expressed
from differential splicing of a single transcript (Dong et al.,
1994; Tan et al., 1994; Thierry and Yaniv, 1987). Expression of
the chimeric GFP-E2 protein, as confirmed by real-time PCR
(Figure 6A, upper), western blot (data not shown), and flow
cytometry (data not shown), promoted a 90% decrease of HPV
E6/E7 transcription. Expression of GFP-E2 also increased the
p53 protein levels (Figure 6A, lower) as previously described
(Desaintes et al., 1997; Thierry et al., 2004) and as expected
from the repression of E6, which, together with the ubiquitin
ligase E6AP, is able to degrade p53 (Scheffner et al., 1990).
Downregulation of the E6/E7 mRNAs in HK-HPV cells induced
a small but significant decrease of the intracellular levels of
CXCL12 24 hr after transduction when compared to control cells
(Figure 6B) and a stronger decrease in the cell surface expres-
sion of both CXCR4 and CXCR7 receptors (Figures 6C and
6D). A decrease of CXCL12 levels was also observed after
silencing of E6 and E7 by a small interfering RNA (data not
shown), thus confirming that these viral oncogenes are direct
inducers of the expression of CXCL12 and its receptors.
Expression of the WHIM Syndrome-Associated Mutant
CXCR41013 Confers HPV18-Immortalized Keratinocytes
with Transforming Capacity
Our data demonstrated that the E6 and E7 oncoproteins control
the expression of CXCL12 and its receptors, which, in turn,
activate signaling pathways that regulate cell migration and
survival. Given the malignant evolution of HPV-induced lesionsecember 16, 2010 ª2010 Elsevier Inc. 527
Figure 5. CXCL12-Mediated Cell Prolifera-
tion and Survival Involve Interaction with
CXCR7
(A) Proliferation of HK-HPV cells was evaluated
with BrdU incorporation. Cells were incubated in
medium containing the indicated concentrations
of chalcone 4 (left, n = 4) or the CXCR7-neutral-
izing 9C4 mAb (middle, n = 3). Cells expressing
nontargeting small hairpin RNA (shScramble) or
shRNA targeting CXCR7 (shCXCR7) were also
used (right, n = 2 experiments performed in tripli-
cates). Results are means ± SEM normalized to
nontreated cells (without inhibitor, mAb, or
shScramble-expressing cells) set at 100%.
*p < 0.05, **p < 0.005, and ***p < 0.0005.
(B) Representative histograms (n = 2) of cell
surface staining of CXCR7 (left) or CXCR4 (right)
compared with isotype control staining (gray) in
HK-HPV18 cells expressing shCXCR7 (red) or
shScramble (blue). Results were analyzed as in
Figures 4C and 3A, respectively. Values are MFIs
of receptor staining.
(C) Early apoptosis of HK-HPV18 cells was evalu-
ated by staining with FITC-conjugated Annexin-V
in the presence (blue) or absence (gray) of 10 mM
chalcone 4 (n = 2–3 experiments performed in
duplicates). Values areMFIs of Annexin-V staining.
(D–F) Western blots (upper) and densitometric
analyses (lower) showing relative levels of total
Akt (Akt-total) and Akt phosphorylated on serine
473 (Akt-Pser473) in HK-Normal (D) or HK-HPV18
(D–F) cells (n = 2–4). Extracts were from
HK-HPV18 cells treated or not overnight with chal-
cone 4 (E) and 9C4 mAb (F, left) or from cells in-
fected for 72 hr with lentivirus expressing
shCXCR7 or shScramble (F, right). Akt-Pser473/
Akt-total ratios ± SEM are normalized to those of
control cells (HK-Normal cells [D], nontreated
cells [E, left of F], or cells expressing shScramble
[F, right]) that are set at 1. *p < 0.05 and
***p < 0.0005. See also Figures S3 and S5.
Cell Host & Microbe
CXCL12/HPV-Interplay and Tumorigenesisin WHIM patients, we hypothesized that the enhanced activation
of the CXCL12-signaling axis downstream from the mutant
receptor CXCR41013 may provide conditions supportive of onco-
genic transformation. When expressed in model cells, the
mutant receptors exhibit enhanced activity, as do receptors in
patients’ cells, thus highlighting their functional prevalence
(Balabanian et al., 2005b; Kawai et al., 2005; Lagane et al., 2008)
and suggesting that the clinical manifestations may be due to
CXCR4 dysfunctions. Because expression of the E6 and E7
oncogenes is not sufficient for full transformation of keratino-
cytes, we investigated whether expression of the CXCR4mutant
receptor in HK-HPV18 could confer these cells with the capacity
to develop solid tumors in nude mice. Cell populations express-
ing equivalent levels of the wild-type (GFP-CXCR4wt) or the
mutant (GFP-CXCR41013) receptors and in a range similar to
the endogenous CXCR4 levels (see Figure 3A, HK-HPV18, red
curve, and Figure S4A, blue curve) were collected by sorting
for GFP expression and were characterized in functional assays
(see also Figure S4). Equal numbers of cells were then injected528 Cell Host & Microbe 8, 523–533, December 16, 2010 ª2010 Elsesubcutaneously into the right flank of nude mice, and tumor
development was monitored for 4 weeks. Mice injected with
HK-HPV cells expressing GFP-CXCR41013 developed detect-
able tumors (only subcutaneous growth > 2 mm in diameter
was considered; Figure 7A, upper) as early as 5 days postinjec-
tion (p.i.); the tumors reached a stable size by week 2 p.i. (median
tumor size, 85.7 ± 23.1 mm3; Figure 7B). In contrast, mice
injected with HK-18/CXCR4wt cells only developed small
tumor-like masses (nodules) 10 days p.i. (median tumor size,
9.1 ± 6 mm3) that did not increase over time (Figures 7A, lower,
and 7B). A similar result was obtained in mice injected with cells
expressing the control vector encoding theGFP protein (data not
shown). Immunohistological analyses of HK-18/CXCR41013
tumors showed a solid and homogeneous morphology in
hematoxylin and eosin (H&E) staining (Figure 7C, left). We
noticed the presence of erythrocyte-filled blood vessels (Fig-
ure 7C, left and arrows), which was confirmed by the staining
of CD31-positive endothelial cells (Figure 7C, right, arrowheads).
Therefore, the aberrant signaling downstream CXCL12-CXCR4vier Inc.
Figure 6. HPV-E6/E7 Expression Is Responsible
for the Increased Levels of CXCL12 and Its Recep-
tors
(A) Upper: HPV18-E2 and -E6/E7 mRNA levels were
measured by real-time PCR in HK-HPV18 cells expressing
HPV18-GFP-E2 or GFP alone and were normalized to
GADPH mRNA levels set at 1. Data are mean ± SEM
(n = 4). Lower: Levels of p53 protein (mean ± SEM) normal-
ized to those of cells expressing GFP set at 1 (n = 4).
(B–D) Effect of E6/E7 downregulation on the expression of
CXCL12 (B), CXCR4 (C), and CXCR7 (D) detected as
described in legends to Figures 1B, 3A, and 4C, respec-
tively. Left: Results are expressed as MFI ± SEM (n = 4).
*p < 0.05 and **p < 0.005 compared with cells expressing
GFP alone. Representative dot plots (right) showed cell
surface expression of CXCR4 (C) andCXCR7 (D) as a func-
tion of GFP fluorescence intensity. Upper right quadrants
contain cells that are positive for both HPV18-GFP-E2 and
CXCR4 or CXCR7. See also Figure S5.
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a crucial contribution of the CXCL12-axis to HPV-induced
oncogenesis.DISCUSSION
We showed here that CXCL12 and its receptors are abnormally
expressed in keratinocytes immortalized by high-risk HPV16 orCell Host & Microbe 8, 523–HPV18 in a manner that depends upon E6 and
E7 oncoprotein expression. Conversely, the
fact that CXCL12-signaling axis is involved in
migration and survival of the keratinocytes high-
lights its relevance to HPV-induced cell transfor-
mation. Moreover, ectopic expression of the
WHIM-associated CXCR41013 mutant receptor
conferred HPV-immortalized keratinocytes
with the capacity to form tumors in xenografted
nude mice. This indicates that signaling path-
ways set in motion downstream the mutant
CXCR4 by engagement of autocrine CXCL12
provide conditions supportive of oncogenic
transformation. Although this mutant receptor
is refractory to CXCL12-induced desensitization
and thus displays an increased G protein-
dependent signaling, it also concomitantly trig-
gers altered b-arrestin-dependent responses
(Lagane et al., 2008; McCormick et al., 2009).
Such abnormal overlap in signaling pathways
may generate novel cellular responses (Rubin,
2009) that could therefore contribute to HPV
pathogenesis in WHIM syndrome. This role of
the CXCL12-dependent signaling in the trans-
formation of human keratinocytes by HPV is
reminiscent of the reported function of this
axis in the development of other human tumors
(Kryczek et al., 2007). Beside a pivotal role for
the CXCL12-CXCR4 pair in cancer metastasis,
this axis is proposed to enhance primary tumor
growth. For instance, CXCL12 secreted byfibroblasts from breast carcinomas promotes tumor growth by
acting through CXCR4 expressed on cancer cells and contrib-
utes to tumor angiogenesis (Orimo et al., 2005). CXCR4, when
ectopically expressed in carcinoma cells, enhances primary
tumor growth in mouse xenograft models (Darash-Yahana
et al., 2004). Although CXCR7 contribution to CXCL12 functions
has been recently questioned, studies have correlated tumor
growth with enhanced expression of this receptor in tumor cells
and the associated vessels (Maksym et al., 2009). It was also533, December 16, 2010 ª2010 Elsevier Inc. 529
Figure 7. Expression of the WHIM Syndrome-
Associated Mutant CXCR41013 Confers HPV18-
Immortalized Keratinocytes with Transforming
Capacity
(A) HK-HPV18 cells (2 3 107) expressing GFP-tagged
CXCR4wt (HK-18/CXCR4wt) or CXCR41013 receptor (HK-
18/CXCR41013) at similar levels were inoculated subcuta-
neously into athymic nude mice. Tumors were photo-
graphed 27 days p.i.
(B) Tumor growth curve plotted with the tumor average
volume (mm3±SEM) ineachgroup (n=3–6mice) asa func-
tion of time. Representative curves (n = 3 for HK-18/
CXCR4wt and n = 5 for HK-18/CXCR41013) are shown.
(C) Representative tumor (day 20 p.i.) from HK-18/
CXCR41013 cells-injected mice was stained with H&E or
with an anti-CD31 mAb that labels erythrocyte-filled blood
vessels (arrows, left; brown staining andarrowheads, right).
The original magnification was 403. See also Figure S4.
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CXCL12/HPV-Interplay and Tumorigenesisreported that expression of CXCR7, which is induced by Kapo-
si’s sarcoma-associated herpes virus, can enhance the tumori-
genicity of fibroblasts in nude mice (Raggo et al., 2005). These
observations raise the possibility that CXCR7, which participates
in the proliferative and prosurvival functions of CXCL12 in
HPV-immortalized keratinocytes, also contributes to cell
transformation.
We could not correlate the mechanism of CXCL12-CXCR4/
CXCR7 upregulation in HPV-associated keratinocytes with tran-
scriptional activation (data not shown). Nevertheless, we found
that interfering with the constitutive activation of the PI3K/Akt
pathway diminished CXCR4 protein levels (see also Figure S5),
which is consistent with the proposed role of this pathway in
the receptor turnover (Li et al., 2004; Slagsvold et al., 2006).
Thus, the E6 and/or E7 proteins could modulate CXCR4 levels
in HPV-associated cells by inducing its stabilization that would
counteract receptor degradation following CXCL12-engage-
ment (Busillo and Benovic, 2007). This function of the E6 and
E7 proteins of high-risk HPVs emphasizes their multifunctional
role in initiation and maintenance of keratinocyte transformation
in vivo. Notably, E6 can induce degradation of p53 and activate
telomerase, whereas E7 downregulates the pRB protein, thus
activating the E2F transcription factors and promoting the entry
in S-phase (Howie et al., 2009; McLaughlin-Drubin and Mu¨nger,
2009). Although the E6 and E7 proteins of low-risk HPVs interact
with fewer cellular partners, our observation that CXCL12 is
expressed in low-risk HPV-induced lesions (Balabanian et al.,
2005b) predicts that the E6 and E7 proteins of these viruses
also activate the CXCL12-CXCR4/CXCR7 pathway. However,
and more generally, comparative studies between high- and
low-risk HPVs remain hampered by the lack of in vitro models
for low-risk HPVs. Low-risk HPVs’ early proteins are unable to530 Cell Host & Microbe 8, 523–533, December 16, 2010 ª2010 Elsevier Inc.immortalize primary keratinocytes, and viral
DNA does not persist in spontaneously immor-
talized keratinocyte lines or in cells derived
from clinical lesions.
The possibility of active signaling through
engagement of CXCL12 to CXCR7 is actively
debated because the receptor does not seem
to activate the typical pertussis toxin-sensitiveGai responses downstream of chemokine receptors (Thelen
and Thelen, 2008). However, our observations that the sustained
PI3K/Akt activation in HPV-immortalized cells is dependent upon
CXCL12-CXCR7 interaction provide further evidence that
CXCR7 is a signaling receptor (Wang et al., 2008). The mecha-
nisms behind this activation, which was insensitive to pertussis
toxin (data not shown), remain elusive, although recent works
indicating that CXCR7 binds to and signals through b-arrestins
after chemokine engagement (Kalatskaya et al., 2009; Rajagopal
et al., 2010; Zabel et al., 2009)make conceivable the contribution
of these uncommon pathways.
Our findings raise questions of a putative role of the CXCL12
autocrine functions in the HPV vegetative cycle. In the natural
course of HPV infection, in which viral particles gain access to
the epithelial basal layer and enter dividing keratinocytes, the
chemokine produced by dermal fibroblasts could increase prolif-
eration and migration of adjacent keratinocytes. This paracrine
activation would in turn enhance cell permissiveness to viral
genome replication and production of the E6 and E7 proteins.
As a consequence, E6 and E7 expressed in the suprabasal layers
would then upregulate levels of CXCL12 and its receptors, which
further enhance cell proliferation and viral DNA replication. This
phenomenon might take place for high- or low-risk HPV infec-
tions and could be enhanced by the gain-of-function mutation
of CXCR4, thus providing a mechanistic basis for the
development of extensive verrucosis in patients with WHIM
and HPV-associated oncogenesis. Development of in vitro
models of the HPV vegetative cycle, such as organotypic models
of human epidermis, will allow this issue to be addressed.
Recent advances in the immortalization of human keratinocytes
(Chapman et al., 2010) may provide a rational for the establish-
ment of cell models for low-risk HPVs.
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tors during the carcinogenic progression of high-risk HPV-asso-
ciated lesions, along with the relationship of these proteins with
viral gene expression and DNA replication in HPV-associated
lesions, are expected to shed light on the cooperation between
the chemokine receptors-signaling axis and the viral life cycle.
These findings could also provide a mechanistic basis for under-
standing why some women are susceptible to HPV-mediated
oncogenesis. Specifically, there may be a genetic predisposition
because of modification of the CXCL12-signaling axis. It will be
important to further investigate the contribution of this pathway
to HPV-related carcinoma progression.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection
Human primary keratinocytes isolated from neonatal foreskin (HK-Normal)
(Lonza) were maintained in defined keratinocyte serum free medium (KSFM)
completed with the provided growth supplements (insulin, epidermal growth
factor, and fibroblast growth factor) and 1% penicillin-streptomycin.
HK-HPV18 and HK-HPV16 cells were obtained upon electroporation of
HK-Normal cells with linearized HPV genomic DNAs as described (Schlegel
et al., 1988). HaCaT cells were transfected with a vector encompassing the
CXCL12 cDNA (Pablos et al., 1999) with the amaxa Nucleofector technology.
Real-Time PCR Analysis
Total RNA was extracted with the RNeasy minikit (QIAGEN) and was reverse
transcribed. Real-time PCR was performed with primers specific for HPV18
E6/E7 andE2 (Table S1). Expression of target geneswas presented as the ratio
to that of human GAPDH used as a control.
Immunofluorescence Assay
Cells (5 3 104) were plated on poly-L-lysine (Sigma-Aldrich)-coated glass
coverslips. After overnight incubation with Brefeldin A (10 mg/mL; Sigma-Al-
drich), intracellular CXCL12 was detected with the mAb clone K15C followed
by incubation with fluoresceine isothiocyanate (FITC)-conjugated goat anti-
mouse IgG (Vector Laboratories). IgG2a was used as matched isotype control
(BD Biosciences PharMingen). Slides were mounted in Mowiol supplemented
with Hoechst 33342 (Molecular Probes), and acquisition of images was
performed as described (Lagane et al., 2008).
Flow Cytometry Analysis
Cell surface staining of CXCL12 was detected with the K15C mAb and flow
cytometry analysis as described (Pablos et al., 1999). For intracellular staining
of CXCL12, cells were treated with Brefeldin A and permeabilised by PBS
supplemented with 0.2% BSA and 0.05% saponin for 20 min at 4C before
staining in the same buffer. When indicated, cells were pretreated with hepar-
itinase I (10 mU/mL; Seikagaku Corporation) at 37C for 30 min to lyse cell
surface HS. HSwas detected with the F58-10E4mAb (Seikagaku Corporation)
and IgM (BD Biosciences PharMingen) was used as the matched control
isotype. Cell-surface expression of CXCR4 and CXCR7 was assessed as
described (Balabanian et al., 2005b) with the phycoerythrin-conjugated anti-
human CXCR4 mAbs 12G5 (BD Biosciences PharMingen) or 6H8 (Mondor
et al., 1998) and the anti-human CXCR7 mAbs 9C4 (Infantino et al., 2006) or
2C10 (which specifically recognizes the N terminus of human CXCR7); all
used at 10 mg/mL. When specified, cells were treated with an acidic buffer
(50 mM Glycine and 120 mM NaCl [pH 2.7] in PBS) before receptor staining.
In some experiments, cell surface levels of receptors were determined 24 hr
after expression of the HPV18-E2 protein fused to the green fluorescent
protein (GFP) (Bellanger et al., 2001) with a lentiviral-based strategy.
Competition Assays of CXCL12-Binding to Receptors
Surface expression of CXCR4 and CXCR7 in HK-HPV18 and HK-HPV16 cells
was also evaluated by competition assays as previously described (Balaba-
nian et al., 2005b). Biotinylated-CXCL12 (biot-CXCL12; 10 nM) was used as
a tracer in the presence of the indicated concentrations of unlabelledCell Host &CXCL12, AMD3100 (Sigma-Aldrich), or interferon-inducible T cell alpha che-
moattractant (I-TAC/CXCL11) (R&D Systems). Cells (2.5 3 105) were pre-
treated with heparitinase I to reduce the nonspecific binding of the biotiny-
lated-chemokine to cell surface HS.
Wound Healing Assays
Cells (1 3 105) (HK-Normal or HK-HPV18) were seeded on poly-L-lysine-
coated coverslips and were grown to confluence in complete KSFM medium.
Scratching and wound healing of cell monolayers were then performed and
analyzed as detailed in the Supplemental Information.
Short Hairpin RNA Expression
The pLKO.1-puro vectors encoding nontargeting (shScramble) or CXCR7-tar-
geted short hairpin RNA (shCXCR7; Table S1) were expressed in growth
factor-deprived cells with a lentiviral-mediated strategy as described (Amara
et al., 2003).
Cell Proliferation Assay and Early Apoptosis Detection
Cells (13 103) were seeded in poly-L-lysine-treated 96-well culture plates with
clear bottom (ViewPlate-96; Perkin Elmer) and then treated for 36 hr in growth
supplement-starved medium with or without the indicated mAbs or inhibitors.
In some experiments, cells were previously infected for 36 hr with shScramble
or shCXCR7. Twelve hours before the end of treatment or lentiviral infection,
cells were incubated with 10 mM BrdU and incorporation (Cell Proliferation
ELISA, BrdU Kit; Roche Applied Science) was measured in a lumi/fluorimetre
Mithras LB940 (Berthold Technologies). Early apoptosis was detected with the
Annexin V-FITC apoptosis detection Kit (PharMingen) after a 24 hr treatment
with chalcone 4 in growth supplement-starvedmedium following themanufac-
turer’s instructions.
Western-Blot Analysis
Akt expression was analyzed by western blot with mAbs specific to either the
total or the ser473-phosphorylated form (Cell Signaling Inc.). Human lactate
dehydrogenase 5 (mouse anti-LDH-5, Biodesign) and SP1 (clone sc-420;
Santa Cruz Biotechnology) were used as loading controls. Unless otherwise
specified, cells were growth supplement starved overnight. Image acquisition
and quantification were performed as described (Lagane et al., 2008). Total
p53 levels were analyzed with themouse anti-p53 antibody (cloneDO-1; Santa
Cruz Biotechnology).
In Vivo HK-HPV18-CXCR41013 Tumor Model in Nude Mice
HK-HPV18 cells stably expressing the T7-GFP-tagged CXCR4wt or CXCR41013
receptors were obtained with a lentiviral-mediated strategy. Cell populations
expressing similar levels of each receptor were acquired through cell sorting
(FACSAria; BD Biosciences) according to GFP expression. Athymic female
nude nu/nu 5-week-old mice (Harlan Laboratories) were injected subcutane-
ously with 2 3 107 HK-HPV18 cells in the right flank (three to six mice per
group). Size of palpable tumors was measured two to three times per week
with a digital caliper. Tumor volumes (V) were calculated as V = p / 6 3
(length 3 width2). Mice were maintained in a pathogen-free animal facility
starting at 4 weeks of age and were fed a standard laboratory diet and tap
water ad libitum and were kept at 23 ± 1C with a 12 hr light/dark cycle. The
Pasteur Institute is licensed by the French Ministry of Agriculture (Agreement
A 75-15-01 to A 75-15-11, dated August 02, 2002) and animal experiments
were performed according to the relevant regulatory standards.
Histology and Immunohistochemistry
Tumors excised from mice were fixed in RCL2 solution (Alphelys), paraffin
embedded, cut into 4 mmsections, andwere stainedwith H&E. Excised tumors
were also cryopreserved upon embedding into the optimum cutting tempera-
ture compound (OCT; Prolabo BDH, VWR International) and were frozen in
liquid nitrogen. Specimens were then sectioned at 4 mm thickness, air-dried,
and fixed in cold acetone for 10 min. Samples were blocked (Vectastain
ABC Peroxidase Kit; Vector Laboratories) and incubated with the anti-CD31
antibody (clone MEC13.3; BD Biosciences PharMingen) followed by the
biotin-conjugated secondary antibodies. Staining was revealed with the
same kit and the 3, 30- diaminobenzidine substrate kit (Vector Laboratories).Microbe 8, 523–533, December 16, 2010 ª2010 Elsevier Inc. 531
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CXCL12/HPV-Interplay and TumorigenesisStatistical Analysis
Student’s t test was used to compare the significance between specified
groups, with p < 0.05 defined as statistically significant. All analysis were per-
formed with Microsoft Excel and GraphPad Prism software (GraphPad Soft-
ware Inc.).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, one table, and one movie and can be found with this article online
at doi:10.1016/j.chom.2010.11.006.
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